Who we are
Axio Biosolutions is India’s leading innovative medtech company with focus on biomaterials. The company offers a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs. Its first product range Axiostat is a USFDA and CE approved product that stops bleeding instantly. Earlier this year, the company launched MaxioCel, a next-generation, chitosan-based advanced wound care dressing that provides comfort and faster healing to patients suffering from chronic wounds.
As the first-ever Indian company to design and launch a novel haemostat for moderate to severe bleeding, Axio Biosolutions has been consistently disrupting the wound care management industry. Its manufacturing facility is ISO 13485 certified and GMP approved, with an ISO 7, Class 10000 cleanroom. Now, with the cutting-edge factory that is 75 per cent automated, boosting the annual capacity to over a million units, the company is all set to conquer new frontiers.
Recently Axio Biosolutions expanded its state-of-the-art manufacturing facility at Gujarat Pharma Techno Park in Ahmedabad, India to over a million units annually and has become the largest chitosan medical sponge manufacturer globally.
Axio's top-notch Scientific Advisory Board, comprises Dr Shiladitya Sengupta, Assistant Professor of Medicine at Harvard Medical School, as Chairman and Dr S V Mahadevan, Professor of Emergency Medicine at Stanford University, as member.
Last year, the company raised $7.4 million in a Series B funding round led by Ratan Tata’s UC- RNT, along with existing investors Accel Partners and IDG Ventures, India.Headquartered in Cambridge, Axio Biosolutions has its corporate office in Bengaluru. The company has strong R&D with multiple patents to its credit.
Wounds cause suffering, pain, long hospital stays, morbidity and even death.
We started on the premise that most of these are preventable.
We demonstrated that it is possible.
We believe in solving such primal issues through innovative use of technology.
We invent and create such tech.
We do not follow.